Edico Genome

edicogenome.com

Based in San Diego and founded in 2013, Edico Genome Inc. develops cutting edge solutions that power the genomic revolution. Our vision is to revolutionize genome sequencing analysis by providing unprecedented speed, scale and accuracy. The “Big Data” Problem: As DNA sequencing costs have plummeted over the last few years, furthered by Illumina’s recent announcement of the ability to sequence genomes for below $1,000, raw data generated by sequencing has increased exponentially, measuring petabytes of data, making analyses and transfer of all this data difficult. These large amounts of data produce a critical bottleneck in the DNA sequencing workflow that has previously only been addressable by throwing increasing numbers of ever more powerful CPU cores at the problem. However, since the data being produced by sequencing already far outpaces Moore’s Law, this solution has very limited sustainability.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industry Outlook

ANDELYN BIOSCIENCES SELECTS TETRASCIENCE AS A STRATEGIC PARTNER FOR INNOVATION IN THERAPEUTICS DEVELOPMENT AND MANUFACTURING

Andelyn Biosciences | August 26, 2021

news image

TetraScience, the R&D Data Cloud company, announced today that Andelyn Biosciences, Inc. has selected the Tetra Data Platform (TDP) to build a cloud-native development and manufacturing service for its customers. As part of an Andelyn Biosciences initiative to create a Connected Plant that harmonizes data from building and facilities, process and manufacturing, and lab instrument sources, TDP will enable better compliance, easier analysis, faster decisions, and more agile operations. Additio...

Read More

Cell and Gene Therapy, Industrial Impact

FULGENT GENETICS LAUNCHES MISSION BIO PLATFORM TO BROADEN ACCESSIBILITY OF SINGLE-CELL MULTI-OMICS FOR DRUG DEVELOPMENT AND CLINICAL RESEARCH

Prnewswire | April 12, 2023

news image

Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced that it has entered into an agreement with Fulgent Genetics a technology-based company with a well-established clinical diagnostic business and a therapeutic development business. Fulgent Genetics is now able to offer single-cell multi-omics on the Tapestri Platform on its fully customizable menu of services, including whole genome, whole exome, RNA sequencing, tumor profiling, methylation...

Read More

Research

MAXCYTE SIGNS CLINICAL AND COMMERCIAL LICENSE WITH SANA BIOTECHNOLOGY

Maxcyte, Inc. | August 12, 2021

news image

MaxCyte, Inc., a leading provider of cell-engineering platform technologies, today announced the signing of a clinical and commercial license with Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines. Under the terms of the agreement, Sana Biotechnology obtains non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform. In return, MaxCyte is entitle...

Read More

GILEAD TO ACQUIRE IMMUNO-ONCOLOGY COMPANY FORTY SEVEN FOR $4.9 BILLION

BioSpace | March 02, 2020

news image

Gilead Sciences is buying Forty Seven for $95.50 per share, or a deal value of $4.9 billion. The deal was unanimously approved by both companies’ boards. Gilead picks up Forty Seven’s lead product candidate, magrolimab, a monoclonal antibody in the clinic for several cancers, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL). Magrolimab targets CD47. Forty Seven presented positive results from a Phase Ib trial of the drug...

Read More
news image

Industry Outlook

ANDELYN BIOSCIENCES SELECTS TETRASCIENCE AS A STRATEGIC PARTNER FOR INNOVATION IN THERAPEUTICS DEVELOPMENT AND MANUFACTURING

Andelyn Biosciences | August 26, 2021

TetraScience, the R&D Data Cloud company, announced today that Andelyn Biosciences, Inc. has selected the Tetra Data Platform (TDP) to build a cloud-native development and manufacturing service for its customers. As part of an Andelyn Biosciences initiative to create a Connected Plant that harmonizes data from building and facilities, process and manufacturing, and lab instrument sources, TDP will enable better compliance, easier analysis, faster decisions, and more agile operations. Additio...

Read More
news image

Cell and Gene Therapy, Industrial Impact

FULGENT GENETICS LAUNCHES MISSION BIO PLATFORM TO BROADEN ACCESSIBILITY OF SINGLE-CELL MULTI-OMICS FOR DRUG DEVELOPMENT AND CLINICAL RESEARCH

Prnewswire | April 12, 2023

Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced that it has entered into an agreement with Fulgent Genetics a technology-based company with a well-established clinical diagnostic business and a therapeutic development business. Fulgent Genetics is now able to offer single-cell multi-omics on the Tapestri Platform on its fully customizable menu of services, including whole genome, whole exome, RNA sequencing, tumor profiling, methylation...

Read More
news image

Research

MAXCYTE SIGNS CLINICAL AND COMMERCIAL LICENSE WITH SANA BIOTECHNOLOGY

Maxcyte, Inc. | August 12, 2021

MaxCyte, Inc., a leading provider of cell-engineering platform technologies, today announced the signing of a clinical and commercial license with Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines. Under the terms of the agreement, Sana Biotechnology obtains non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform. In return, MaxCyte is entitle...

Read More
news image

GILEAD TO ACQUIRE IMMUNO-ONCOLOGY COMPANY FORTY SEVEN FOR $4.9 BILLION

BioSpace | March 02, 2020

Gilead Sciences is buying Forty Seven for $95.50 per share, or a deal value of $4.9 billion. The deal was unanimously approved by both companies’ boards. Gilead picks up Forty Seven’s lead product candidate, magrolimab, a monoclonal antibody in the clinic for several cancers, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL). Magrolimab targets CD47. Forty Seven presented positive results from a Phase Ib trial of the drug...

Read More